Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Takao Miyabayashi"'
Autor:
Kenichi Koyama, Satoru Miura, Satoshi Watanabe, Satoshi Shoji, Jun Koshio, Yoshiki Hayashi, Daisuke Ishikawa, Ko Sato, Takao Miyabayashi, Masaaki Okajima, Takeshi Ota, Tomohiro Tanaka, Naoya Matsumoto, Hideyuki Kuriyama, Tetsuya Abe, Koichiro Nozaki, Kosuke Ichikawa, Rie Kondo, Hiroshi Tanaka, Toshiaki Kikuchi
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-8 (2022)
Abstract The identification of acquired resistance mutations has been essential in non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) active mutations. Rebiopsy plays a pivotal role in selecting the optimal treat
Externí odkaz:
https://doaj.org/article/180f91ed11f74a1faa086a15774d4a22
Autor:
Satoshi Watanabe, Takeshi Ota, Masachika Hayashi, Hiroyuki Ishikawa, Aya Otsubo, Satoshi Shoji, Koichiro Nozaki, Kosuke Ichikawa, Rie Kondo, Takao Miyabayashi, Satoru Miura, Hiroshi Tanaka, Tetsuya Abe, Masaaki Okajima, Masaki Terada, Takashi Ishida, Akira Iwashima, Kazuhiro Sato, Hirohisa Yoshizawa, Toshiaki Kikuchi
Publikováno v:
Cancer Medicine, Vol 9, Iss 9, Pp 3070-3077 (2020)
Abstract Background Interstitial lung disease (ILD) induced by anti‐programmed‐cell death‐1 (PD‐1) and anti‐PD‐ligand 1 (PD‐L1) is potentially life‐threatening and is a common reason of the discontinuation of therapy. In contrast, an
Externí odkaz:
https://doaj.org/article/b15f1897c0a94d74af3eab35d56674ed
Autor:
Toshiya Fujisaki, Satoshi Watanabe, Takeshi Ota, Kohei Kushiro, Yusuke Sato, Miho Takahashi, Aya Ohtsubo, Satoshi Shoji, Koichiro Nozaki, Kosuke Ichikawa, Satoshi Hokari, Rie Kondo, Takao Miyabayashi, Tetsuya Abe, Satoru Miura, Hiroshi Tanaka, Masaaki Okajima, Masaki Terada, Naoya Matsumoto, Takashi Ishida, Akira Iwashima, Kazuhiro Sato, Hirohisa Yoshizawa, Nobumasa Aoki, Masachika Hayashi, Yasuyoshi Ohshima, Toshiyuki Koya, Toshiaki Kikuchi
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
ObjectivesAlthough immune checkpoint inhibitors (ICIs) have been shown to improve overall survival (OS) in advanced non-small-cell lung cancer (NSCLC) patients, ICIs sometimes cause various types of immune-related adverse events (irAEs), which lead t
Externí odkaz:
https://doaj.org/article/ecc089bdf85d4930b1e2d948173bc025
Autor:
Hidenori Kawakami, Takao Miyabayashi, Chikako Tsubata, Kyuma Ota, Takashi Ishida, Osamu Kobayashi
Publikováno v:
Respiratory Medicine Case Reports, Vol 26, Iss , Pp 180-184 (2019)
We retrospectively analyzed the data of 9 patients with organizing pneumonia induced by radiation therapy. Radiation therapy had been administered for breast cancer in 8 patients and for lung cancer in 1 patient. Symptoms were detected in 8 patients;
Externí odkaz:
https://doaj.org/article/083b04f3ff644da4ae7dc41aca4520a4
Autor:
Koh Nakata, Ichiei Narita, Hiroshi Kagamu, Satoshi Watanabe, Takao Miyabayashi, Junko Baba, Takeshi Ota, Hiroshi Tanaka, Koki Matsuyama, Hirohisa Yoshizawa
Publikováno v:
Middle East Journal of Cancer, Vol 2, Iss 1, Pp 9-18 (2011)
Background: Nonmyeloablative chemotherapy followed by adoptiveimmunotherapy is an attractive strategy for depleting regulatory T cells in the host. However, its efficacy is transient. Here, we aim to investigate whether cyclic chemoimmunotherapy has
Externí odkaz:
https://doaj.org/article/3cd61f1a950243f8b1ee120e2b73f224
Autor:
Hiroki Watanabe, Yui Murai, Asumi Suzuki, Ikumi Yamagishi, Eiji Ogata, Takao Miyabayashi, Akira Youkou, Masatoshi Watanabe, Tetsuya Abe
Publikováno v:
Haigan. 62:996-1000
Efficacy and safety of amrubicin therapy after chemoimmunotherapy in small cell lung cancer patients
Autor:
Kohei, Kushiro, Satoshi, Watanabe, Yuka, Goto, Toshiya, Fujisaki, Naohiro, Yanagimura, Aya, Ohtsubo, Satoshi, Shoji, Koichiro, Nozaki, Tomohiro, Tanaka, Yu, Saida, Yusuke, Sato, Takeshi, Ota, Jun, Koshio, Yoshiki, Hayashi, Takao, Miyabayashi, Naoya, Matsumoto, Kosuke, Ichikawa, Kenichi, Koyama, Toshiaki, Kikuchi
Publikováno v:
Translational Lung Cancer Research. 11:1858-1865
Although the addition of immune checkpoint inhibitors (ICIs) to platinum-doublet chemotherapy has improved the efficacy of first-line therapy in extensive-disease small cell lung cancer (SCLC) patients, the best treatment option for patients with rec
Autor:
Yuji Minegishi, Tomoe Akagami, Makoto Arai, Ryota Saito, Daisuke Arai, Kyoko Murase, Keita Miura, Satoshi Watanabe, Hiroyuki Sakashita, Takao Miyabayashi, Ryoichi Honda, Daisuke Jingu, Takamasa Hotta, Kazutoshi Isobe, kensuke Nakazawa, Kenichiro Ito, Kei Takamura, Minehiko Inomata, Toshiyuki Harada, Rie Sakakibara, Taku Nakagawa, Hideki Shibuya, Kiyoshi Takenaka, Kunihiko Kobayashi, Masahiro Seike
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 172
Malignant tumors are the major cause of death in hemodialysis patients. Management of these patients remains challenging as there is no evidence that chemotherapy is beneficial, and a lack of information about actual clinical practice.This multicente
Autor:
Rie Kondo, Satoru Miura, Akira Iwashima, Hiroyuki Ishikawa, Aya Otsubo, Masaaki Okajima, Satoshi Shoji, Satoshi Watanabe, Hiroshi Tanaka, Kazuhiro Sato, Kosuke Ichikawa, Tetsuya Abe, Takashi Ishida, Takao Miyabayashi, Hirohisa Yoshizawa, Masachika Hayashi, Koichiro Nozaki, Masaki Terada, Takeshi Ota, Toshiaki Kikuchi
Publikováno v:
Cancer Medicine, Vol 9, Iss 9, Pp 3070-3077 (2020)
Cancer Medicine
Cancer Medicine
Background Interstitial lung disease (ILD) induced by anti‐programmed‐cell death‐1 (PD‐1) and anti‐PD‐ligand 1 (PD‐L1) is potentially life‐threatening and is a common reason of the discontinuation of therapy. In contrast, an enhanceme
Autor:
Kenichi Koyama, Satoru Miura, Satoshi Watanabe, Satoshi Shoji, Jun Koshio, Yoshiki Hayashi, Daisuke Ishikawa, Ko Sato, Takao Miyabayashi, Masaaki Okajima, Takeshi Ota, Tomohiro Tanaka, Naoya Matsumoto, Hideyuki Kuriyama, Tetsuya Abe, Koichiro Nozaki, Kosuke Ichikawa, Rie Kondo, Hiroshi Tanaka, Toshiaki Kikuchi
Publikováno v:
Scientific reports. 12(1)
The identification of acquired resistance mutations has been essential in non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) active mutations. Rebiopsy plays a pivotal role in selecting the optimal treatment for